Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...

This study has been completed.
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ) Identifier:
First received: September 21, 2013
Last updated: August 6, 2016
Last verified: August 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2015
  Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)